Growth Metrics

Eli Lilly (LLY) Long-Term Deferred Tax (2017 - 2025)

Eli Lilly's Long-Term Deferred Tax history spans 9 years, with the latest figure at $10.0 billion for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax rose 24.47% year-over-year to $10.0 billion; the TTM value through Dec 2025 reached $10.0 billion, up 24.47%, while the annual FY2025 figure was $10.0 billion, 24.47% up from the prior year.
  • Long-Term Deferred Tax reached $10.0 billion in Q4 2025 per LLY's latest filing, up from $9.0 billion in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $10.0 billion in Q4 2025 to a low of $2.4 billion in Q2 2022.
  • Average Long-Term Deferred Tax over 5 years is $5.1 billion, with a median of $4.2 billion recorded in 2023.
  • Peak YoY movement for Long-Term Deferred Tax: dropped 12.05% in 2021, then skyrocketed 96.12% in 2023.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $2.5 billion in 2021, then grew by 12.2% to $2.8 billion in 2022, then skyrocketed by 96.12% to $5.5 billion in 2023, then surged by 46.08% to $8.0 billion in 2024, then increased by 24.47% to $10.0 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Long-Term Deferred Tax are $10.0 billion (Q4 2025), $9.0 billion (Q3 2025), and $9.4 billion (Q2 2025).